Progenity, Inc. Stock News

New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Silk Road" or the "Company") (NASDAQ: PROG). Such investors ar

SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing pr

NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc.  ("Silk Road" or the "Company") (NASDAQ: PROG).  Such investors are advised

New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Silk Road" or the "Company") (NASDAQ: PROG). Such investors are

NEW YORK, March 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Silk Road" or the "Company") (NASDAQ: PROG). Such investors are advised to con

SAN DIEGO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing mol

New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. (NASDAQ: PROG) ("Silk Road" or the "Company"). Such investors

NEW YORK, Feb. 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Silk Road" or the "Company") (NASDAQ: PROG). Such investors are advised to con

SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing produc

New York, New York--(Newsfile Corp. - February 15, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Silk Road" or the "Company") (NASDAQ: PROG). Such investors

Progenity applauds focus on preeclampsia biomarkers as it prepares for the launch of the Preecludia™ test Progenity applauds focus on preeclampsia biomarkers as it prepares for the launch of the Pre

New York, New York--(Newsfile Corp. - February 11, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Silk Road" or the "Company") (NASDAQ: PROG). Such investors

SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing pro

Progenity's (NASDAQ:PROG) stock has been falling Monday, down 6.19% to a price of $5.9. Monday the stock has been traded at a volume of 209.31 thousand, about 29.44% of its recent 30-day volume averag

The company celebrates its ten-year anniversary and looks toward future innovations The company celebrates its ten-year anniversary and looks toward future innovations